Hidradenitis suppurativa (HS)
HUMIRA is the first and only originator biologic* indicated in the treatment of HS†
HUMIRA is indicated for the treatment of active moderate to severe HS in adult and adolescent patients (12 to 17 years of age weighing ≥30 kg), who have not responded to conventional therapy (including systemic antibiotics).
* Also known as a reference biologic.
† Comparative clinical significance has not been established.
AbbVie Care: Continued support for your HUMIRA patients, every
step of the way
Continuing to put your HUMIRA patients' support needs front and centre
FOR MORE INFORMATION
The abbviecare.ca website is open to the general public
Safety information
Click here for additional information and for a link to the Product Monograph discussing:
• Contraindications in patients with severe infections such as sepsis, tuberculosis (TB) and opportunistic infections, and moderate to severe heart failure (NYHA class III/IV).
• The most serious warnings and precautions regarding hepatosplenic T-cell lymphoma, serious infections and pediatric malignancy.
• Other relevant warnings and precautions regarding concurrent administration with other biologic disease-modifying antirheumatic drugs (DMARDs) or other tumour necrosis factor (TNF) antagonists not recommended, switching between biological DMARDs, surgery, patients with congestive heart failure, hematologic events, hypersensitivity reactions, autoimmunity, immunosuppression, immunizations, infections including TB, opportunistic infections and hepatitis B virus reactivation, malignancies including malignancies in pediatric patients and young adults, lymphoma and non-lymphoma malignancy, neurologic events, uveitis and central demyelinating disorders, pregnant or nursing women, and geriatrics.
• Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.
The Product Monograph is also available by calling us at 1-866-8HUMIRA (1-866-848-6472).
Reference:
1. AbbVie Corporation Data on File.